Last year, a new crop of biotechnology exchanged-traded funds brought refined, laser-like focus to the fast-growing market segment.
Biotech ETFs making their debuts in late 2014 included funds devoted exclusively to companies with products in specific stages of clinical trials or only to those companies that have received at least one FDA approval.
New Biotech ETF Joins Growing List
Add the Loncar Cancer Immunotherapy ETF (NASDAQ: CNCR) to the list of new, focused biotech ETFs. The Loncar Cancer Immunotherapy ETF, which debuted Wednesday, is the first ETF exclusively devoted to cancer immunotherapy.
Exchange Traded Concepts, LLC (ETC), Loncar Investments, ISE ETF Ventures and Amplify Development LLC partnered to bring the Loncar Cancer Immunotherapy ETF to market.
The new ETF ...
/www.benzinga.com/general/biotech/15/10/5913057/biotech-etfs-get-more-refined-with-debut-of-cancer-immunotherapy-fund alt=Biotech ETFs Get More Refined With Debut Of Cancer Immunotherapy Fund>Full story available on Benzinga.com
More...